Figure 2 Protective efficacy of these Cap-3M2e VLPs against
IAV.
(a) Human IAV M2e-specific IgG level (n=6). (b) Swine IAV M2e-specific
IgG level (n=6). (c) Avian IAV M2e-specific IgG level (n=6). (d) Mice
body weight changes (n=5), (e) survival rate (n=5) and (f) lung virus
titers (n=4) post 10 × LD50 of A/Puerto Rico/8/1934
(H1N1) challenge. (g) Mice body weight changes (n=5), (h) survival rate
(n=5) and (i) lung virus titers (n=4) post 10 × LD50 of
A/swine/Zhucheng/90/2014 (H1N1) challenge. (j) Mice body weight changes
(n=5), (k) survival rate (n=5) and (l) lung virus titers (n=4) post 40
µL 109 TCID50/mL of
A/chicken/Guangzhou/GZ/2005 (H9N2) challenge. p < 0.05 (*).